Predicted decreases in deaths expressed as a percentage of total expected CHD deaths in 2030 –Ideal & Modest Future Risk Factor Scenarios. by John Hughes (650501)

MiR-133a expression decreases cancer metastasis <i>in vivo</i> and associates with longer survival rates in NSCLC patients. by Lu-Kai Wang (562118)

Supplementary Material for: Adult Patients with Hbs-Only Phenotype of Sickle Cell Disease have a Decreased Arginine/Asymmetric Dimethylarginine Ratio by figshare admin karger (2628495)

Data_Sheet_1_Decreasing Biological Production and Carbon Export Due to the Barrier Layer: A Case Study in the Bay of Bengal.docx by Huangchen Zhang (11439883)

Data_Sheet_1_Decreasing the carbon footprint of food through public procurement—A case study from the municipality of Härnösand.PDF by Mari Kjellberg (20130183)

NHEJ-independent random integration is significantly decreased when a homology arm is deleted from the <i>HPRT</i> targeting vector. by Ayako Ishii (633502)

A PPARα Promoter Variant Impairs ERR-Dependent Transactivation and Decreases Mortality after Acute Coronary Ischemia in Patients with Diabetes by Sharon Cresci (53599)

The ATM inhibitor KU55933 decreases the radiation resistance of stem-like MDA-MB-231, Patient A, and Patient B cells. by Hong Yin (20329)

Data Sheet 1_Prehospital tranexamic acid decreases early mortality in trauma patients: a systematic review and meta-analysis.docx by Yi Li (1144)

“…Compared to the control group, the prehospital TXA group exhibited a significant reduction in 24-h mortality with an OR of 0.72 and a 95% CI of 0.54–0.94 (p = 0.02), while no statistically significant difference in the incidence of venous thromboembolism (VTE; OR: 1.14, 95% CI: 0.98–1.33, p = 0.09). …”

Detailed prevalence data from gnomAD [24] for ACE2 variants reported in Table 1. by Stuart A. MacGowan (11326845)

Subjects:

The structure of ACE2 (green) gnomAD [24] missense variant p.Lys26Arg that enhances Spike (light blue) binding affinity. by Stuart A. MacGowan (11326845)

Subjects:

Structural description of the ACE2 –Spike-protein interface. by Stuart A. MacGowan (11326845)

Subjects:

mCSM-PPI2 predicted ΔΔG with and without recalibration are in agreement with published deep mutagenesis binding data [22] at low predicted ΔΔG but recalibrated predictions are more... by Stuart A. MacGowan (11326845)

Subjects:

Estimated allele frequencies of potential novel variants in ACE2 with predicted Spike binding phenotypes. by Stuart A. MacGowan (11326845)

Subjects:

mCSM-PPI2 predictions for all gnomAD ACE2 missense variants in residues resolved in PDB 6vw1. by Stuart A. MacGowan (11326845)

Subjects:

Distribution of mCSM-PPI2 [13] predicted ΔΔG from in silico saturation mutagenesis of the ACE2-S interface in PDB 6vw1 [11]. by Stuart A. MacGowan (11326845)

Subjects:

Surface plasmon resonance derived ΔΔG and mCSM-PPI2 [13] predictions for ACE2 mutants, including gnomAD [24] missense variants, at or near the ACE2 Spike interface. by Stuart A. MacGowan (11326845)

Subjects:

The relationship between experimental and predicted ΔΔG of ACE2 mutants and relative SARS-CoV-2 pseudotype infectivity reported by Shukla et al [38]. by Stuart A. MacGowan (11326845)

Subjects:

The structure of ACE2 (green) gnomAD [24] missense variant p.Ser19Pro that enhances Spike (light blue) binding affinity. by Stuart A. MacGowan (11326845)

Subjects:

Binding affinity determination of ACE2 variants with SARS-CoV-2 Spike. by Stuart A. MacGowan (11326845)

Subjects: